Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2012

01-04-2012 | Letter to the Editor

Elucidating disparities across racial and ethnic groups in multiple myeloma patients

Authors: Alexandra J. Greenberg, S. Vincent Rajkumar

Published in: International Journal of Hematology | Issue 4/2012

Login to get access

Excerpt

Several studies have established trends in the prevalence and incidence of multiple myeloma (MM) across races. Kaya et al. [1] recently shared findings using data from the Surveillance, Epidemiology, and End Results (SEER) program that not only confirm some of these trends, but also introduce data for demographics not previously studied in-depth. …
Literature
1.
Kaya H, Peressini P, Jawed I, et al. Impact of age, race, and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol. 2012;95:64–70.PubMedCrossRef
2.
Bowden M, Crawford J, Cohen H, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc. 1993;41:11–4.PubMed
3.
Parkin D, Whelan S, Ferlay J, Teppo L, Thomas D. Cancer incidence in five continents, vol. VIII. Lyon: International Agency for Research on Cancer; 2002.
4.
Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City Japan. Mayo Clin Proc. 2007;82:1474–9.PubMedCrossRef
5.
Rajkumar S, Jacobus S, Callander N, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.PubMedCrossRef
6.
Landgren O, Weiss B. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.PubMedCrossRef
7.
Greenberg A, Vachon C, Rajkumar S. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2011. doi:10.​1038/​leu.​2011.​368.PubMed
8.
Weiss B, Minter A, Abadie J, et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am J Hematol. 2011;86:475–8.PubMedCrossRef
9.
Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities—racial and ethnic approaches to community health across the U.S. (REACH U.S.) Risk Factor Survey, United States, 2009. MMWR Surveill Summ. 2011;60:1–44.PubMed
10.
Watanabe-Galloway S, Flom N, Xu L, et al. Cancer-related disparities and opportunities for intervention in Northern Plains American Indian communities. Public Health Rep. 2011;126:318–29.PubMed
Metadata
Title
Elucidating disparities across racial and ethnic groups in multiple myeloma patients
Authors
Alexandra J. Greenberg
S. Vincent Rajkumar
Publication date
01-04-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1040-y

Other articles of this Issue 4/2012

International Journal of Hematology 4/2012 Go to the issue

Progress in Hematology

Guest editorial: current understanding of thrombosis and hemostasis—from bench to bedside

Original Article

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study

Case Report

Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation

Original Article

Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy

Review Article

High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility?

Original Article

Screening for co-existence of α-thalassemia in β-thalassemia and in HbE heterozygotes via an enzyme-linked immunosorbent assay for Hb Bart’s and embryonic ζ-globin chain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits